Table 2 Incidence of complete donor-type chimerism.

From: Treosulfan–fludarabine–thiotepa-based conditioning treatment before allogeneic hematopoietic stem cell transplantation for pediatric patients with hematological malignancies

 

Treosulfan

Subjects at risk at day +28 visita

N = 64

 Subjects with complete chimerism at day +28 visit [n (%)]

63 (98.4)

 90% CI

(92.8, 99.9)

 Subjects without information at day +28 visit [n (%)]

1 (1.6)

Subjects at risk at day +100 visita

N = 64

 Subjects with complete chimerism at day +100 visit [n (%)]

59 (92.2)

 90% CI

(84.3, 96.9)

 Subjects without information at day +100 visit [n (%)]

5 (7.8)

Subjects at risk at month 12 visita

N = 54

 Subjects with complete chimerism at month 12 visit [n (%)]

50 (92.6)

 90% CI

(83.8, 97.4)

 Subjects without information at month 12 visit [n (%)]

2 (3.7)

  1. CI confidence interval, N number of subjects, n number of subjects in category.
  2. aSubjects are at risk if they have a chimerism examination at the day +28, day +100, or month 12 visit or if they have survived day +30, day +107, or day +379.
Back to article page